Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients

European Journal of Neurology

Volumn 17, Issue 5, 2010, Pages 661-665

  Belcastro, V ^a   Pierguidi, L ^a   Castrioto, A ^a   Menichetti, C ^a   Gorgone, G ^b   Ientile, R ^c   Pisani, F ^c   Rossi, A ^a   Calabresi, P ^a   Tambasco, N ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Folate; Hyperhomocysteinemia; Levodopa; Parkinson's disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); COBALAMIN; FOLIC ACID; LEVODOPA;

AGED; ARTICLE; CLINICAL ARTICLE; DRUG PULSE THERAPY; FEMALE; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE;

AGED; CROSS-SECTIONAL STUDIES; DOPAMINE AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; VITAMIN B 12;

EID: 77950887076     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02894.x     Document Type: Article

References (31)

1. Nakaso K, Yasui K, Kowa H, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with levodopa, homocysteine and MTHFR genotype. J Neurol Sci 2003 207 : 19 23. (Pubitemid 36287098)
2. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003 60 : 59 64. (Pubitemid 36078109)
3. O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine levels in patients in patients with Parkinson Disease: motor, affective, and cognitive associations. Arch Neurol 2004 61 : 865 868. (Pubitemid 38747325)
4. Zoccolella S, dell'Aquila C, Abruzzese G, et al. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov Disord 2009 24 : 1028 1033.
5. Zoccolella S, Lamberti P, Iliceto G, et al. Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clin Chem Lab Med 2006 44 : 863 866. (Pubitemid 43911561)
6. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004 19 : 1403 1408. (Pubitemid 40109481)
7. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003 60 : 1125 1129. (Pubitemid 36418772)
8. de Lau LM, Koudstaal PJ, van Meurs JB, Uitterlinden AG, Hofman A, Breteler MM. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol 2005 57 : 927 930. (Pubitemid 40798634)
9. Chango A, Boisson F, Barbé F, et al. The effect of 677C - >T and 1298A - >C mutations on plasma homocysteine and 5,10- methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 2000 83 : 593 596. (Pubitemid 30392098)
10. Lamberti P, Zoccolella S, Armenise E, et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005 12 : 365 368. (Pubitemid 40524176)
11. Postuma RB, Espay AJ, Zadikoff C, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006 66 : 1941 1943. (Pubitemid 44049836)
12. Herrmann W, Herrmann M, Obeid R. Hyperhomocysteinemia: a critical review of old and new aspects. Curr Drug Metab 2007 8 : 17 31. (Pubitemid 46043889)
13. Belcastro V, Gorgone G, Italiano D, et al. Antiepileptic drugs and MTHFR polymorphisms influence hyperhomocysteinemia recurrence in epileptic patients. Epilepsia 2007 48 : 1990 1994. (Pubitemid 47537442)
14. Caccamo D, Gorgone G, Currò M, et al. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated parkinsonian patients. Neuromolecular Med 2007 9 : 249 254. (Pubitemid 350129699)
15. Reynolds EH. Vitamin B12, folic acid, and the nervous system. Lancet Neurol 2006 5 : 949 960. (Pubitemid 44556551)
16. Religa D, Czyzewski K, Styczynska M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett 2006 404 : 56 60. (Pubitemid 44063604)
17. Ozer F, Meral H, Hanoglu L, et al. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 2006 28 : 853 858. (Pubitemid 44904462)
18. Hassin-Baer S, Cohen O, Vakil E, et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006 29 : 305 311. (Pubitemid 44729941)
19. Hankey GJ. Is homocysteine a causal and treatable risk factor for stroke? Lancet Neurol 2007 6 : 751 752. (Pubitemid 47238667)
20. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007 6 : 830 838. (Pubitemid 47241275)
21. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007 369 : 1876 1882. (Pubitemid 46829358)
22. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke myocardial infarction, and death: the Vitamin Intervention for Stroke prevention (VISP) randomized controlled trial. JAMA 2004 291 : 565 575.
23. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006 354 : 1578 1588.
24. Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behaviour rodents. Neurotoxicology 2005 26 : 361 371. (Pubitemid 40780013)
25. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005 118 : 1250 1255. (Pubitemid 41566526)
26. Woitalla D, Kuhn W, Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. J Neural Transm 2004 68 : 15 20. (Pubitemid 39215433)
27. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001 22 : 195 201. (Pubitemid 32244306)
28. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003 26 : 137 146. (Pubitemid 36183675)
29. Cai H, Wang X, Colagiuri S, Wilcken DE. Methionine synthase D919G mutation in type 2 diabetes and its relation to vascular events. Diabetes Care 1998 10 : 1774 1775. (Pubitemid 28449824)
30. de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 2006 67 : 315 318.
31. Chen H, Zhang SM, Scharzschild MA, et al. Folate intake and risk of Parkinson' disease. Am J Epidemiol 2004 27 : 561 568.